PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDiatrizoic acid
Diatrizoic acid
Cystografin, Diatrizoate Diatrizoate, Gastrografin, Hypaque, Md, Md-gastroview, Sinografin, Urovist (diatrizoic acid) is a small molecule pharmaceutical. Diatrizoic acid was first approved as Cystografin on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Diatrizoate meglumine diatrizoate, Gastrografin, Md-gastroview (discontinued: Angiovist, Diatrizoate, Gastrovist, Hypaque, Md, Md-76r, Renocal)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diatrizoate sodium
Tradename
Company
Number
Date
Products
HYPAQUEGE HealthcareN-011386 DISCN1982-01-01
2 products
HYPAQUEGE HealthcareN-009561 DISCN1982-01-01
1 products
HYPAQUE SODIUM 20%GE HealthcareN-009561 DISCN1982-01-01
1 products
HYPAQUEGE HealthcareN-009561 DISCN1982-01-01
1 products
Hide discontinued
Diatrizoate meglumine
+
Diatrizoate sodium
Tradename
Company
Number
Date
Products
GASTROGRAFINBracco DiagnosticsN-011245 RX1982-01-01
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cystografinNew Drug Application2018-04-15
cystografin diluteNew Drug Application2018-10-02
diatrizoate meglumine and diatrizoate sodiumANDA2025-02-19
gastrografinNew Drug Application2021-10-04
hypaque2006-04-13
hypaque - cysto2007-08-03
hypaque sodium2007-08-03
md gastroviewANDA2021-01-01
md-gastroviewANDA2014-09-29
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V08: Contrast media
— V08A: X-ray contrast media, iodinated
— V08AA: Watersoluble, nephrotropic, high osmolar x-ray contrast media
— V08AA01: Diatrizoic acid
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients——————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDiatrizoic acid
INN_
Description
Amidotrizoic acid is a member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography. It has a role as a radioopaque medium, an environmental contaminant and a xenobiotic. It is an organoiodine compound, a member of benzoic acids and a member of acetamides. It is a conjugate acid of an amidotrizoic acid anion.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
Identifiers
PDB—
CAS-ID117-96-4
RxCUI—
ChEMBL IDCHEMBL1201220
ChEBI ID53691
PubChem CID2140
DrugBankDB00271
UNII ID5UVC90J1LK (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 33,858 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
420 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use